{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:00:42Z","timestamp":1787025642070,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.3109\/14653249.2012.694419","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T11:20:12Z","timestamp":1342524012000},"page":"851-859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["A phase I\/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission"],"prefix":"10.1016","volume":"14","author":[{"given":"Yeh-Ching","family":"Linn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Xiang","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelaine","family":"Niam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsyr-Jong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Choong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow-Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Joo","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garnet","family":"Suck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieta","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3109\/14653249.2012.694419_bib0005","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","article-title":"A novel population of expanded human CD3 + CD56 + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency","volume":"153","author":"Lu","year":"1994","journal-title":"J Immunol"},{"key":"10.3109\/14653249.2012.694419_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"10.3109\/14653249.2012.694419_bib0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2002.03247.x","article-title":"Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts","volume":"116","author":"Linn","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3109\/14653249.2012.694419_bib0020","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood.V92.9.3318","article-title":"Expansion of Philadelphia chromosome-negative CD3(+) CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice","volume":"92","author":"Hoyle","year":"1998","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0025","first-page":"33","article-title":"Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia","volume":"15","author":"Scheffold","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.3109\/14653249.2012.694419_bib0030","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ijc.21994","article-title":"Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma","volume":"119","author":"Kornacker","year":"2006","journal-title":"Int J Cancer"},{"key":"10.3109\/14653249.2012.694419_bib0035","first-page":"1029","article-title":"Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells","volume":"86","author":"Marten","year":"2001","journal-title":"Haematologica"},{"key":"10.3109\/14653249.2012.694419_bib0040","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.exphem.2011.06.005","article-title":"Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy","volume":"39","author":"Niam","year":"2011","journal-title":"Exp Hematol"},{"key":"10.3109\/14653249.2012.694419_bib0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jim.2003.12.007","article-title":"CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases","volume":"285","author":"Ott","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.3109\/14653249.2012.694419_bib0050","first-page":"1653","article-title":"Cancer vaccines for patients with acute myeloid leukemia: definition of leukemia-associated antigens and current clinical protocols targeting these antigens","volume":"91","author":"Greiner","year":"2006","journal-title":"Haematologica"},{"key":"10.3109\/14653249.2012.694419_bib0055","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0060","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0065","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","article-title":"A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS","volume":"113","author":"Keilholz","year":"2009","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0070","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3109\/14653249.2012.694419_bib0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0080","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","article-title":"RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses","volume":"111","author":"Schmitt","year":"2008","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0085","doi-asserted-by":"crossref","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms\u2019 tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Van Tendeloo","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3109\/14653249.2012.694419_bib0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.3109\/14653249.2012.694419_bib0095","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","article-title":"Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"key":"10.3109\/14653249.2012.694419_bib0100","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2009-02-205278","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)","volume":"114","author":"Borrello","year":"2009","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.bmt.1704317","article-title":"Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells","volume":"33","author":"Rapoport","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.3109\/14653249.2012.694419_bib0110","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of CD3 + CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0115","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2567.2008.02910.x","article-title":"Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell","volume":"126","author":"Linn","year":"2009","journal-title":"Immunology"},{"key":"10.3109\/14653249.2012.694419_bib0120","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2010-06-290858","article-title":"Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies","volume":"117","author":"Pievani","year":"2011","journal-title":"Blood"},{"key":"10.3109\/14653249.2012.694419_bib0125","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"10.3109\/14653249.2012.694419_bib0130","first-page":"1","article-title":"The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies","author":"Linn","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.3109\/14653249.2012.694419_bib0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbmt.2004.11.019","article-title":"A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma","volume":"11","author":"Leemhuis","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3109\/14653249.2012.694419_bib0140","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","article-title":"Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma","volume":"81","author":"Schmidt-Wolf","year":"1999","journal-title":"Br J Cancer"},{"key":"10.3109\/14653249.2012.694419_bib0145","first-page":"198","article-title":"The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia","volume":"44","author":"Jiang","year":"2005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.3109\/14653249.2012.694419_bib0150","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","article-title":"Adoptive cell therapy for the treatment of patients with metastatic melanoma","volume":"21","author":"Rosenberg","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.3109\/14653249.2012.694419_bib0155","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-09-0418","article-title":"Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells","volume":"15","author":"Rapoport","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3109\/14653249.2012.694419_bib0160","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI24480","article-title":"Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 + T cells","volume":"115","author":"Gattinoni","year":"2005","journal-title":"J Clin Invest"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912707004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324912707004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:17:01Z","timestamp":1761430621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324912707004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1465324912707004"],"URL":"https:\/\/doi.org\/10.3109\/14653249.2012.694419","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I\/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3109\/14653249.2012.694419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}